FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2127172644> ?p ?o ?g. }

• W2127172644 endingPage "329" @default.
• W2127172644 startingPage "329" @default.
• W2127172644 abstract "To compare efficacy of indacaterol to that of fixed-dose combination (FDC) formoterol and budesonide (FOR/BUD) and FDC salmeterol and fluticasone (SAL/FP) for the treatment of chronic obstructive pulmonary disease (COPD) based on the available randomized clinical trials (RCTs).Fifteen placebo-controlled RCTs were included that evaluated: indacaterol 150 μg (n = 5 studies), indacaterol 300 μg (n = 4), FOR/BUD 9/160 μg (n = 2), FOR/BUD 9/320 μg (n = 3), SAL/FP 50/500 μg (n = 5), and SAL/FP 50/250 μg (n = 1). Outcomes of interest were trough forced expiratory volume in 1 second (FEV(1)), total scores for St. George's Respiratory Questionnaire (SGRQ), and transition dyspnea index (TDI). All trials were analyzed simultaneously using a Bayesian network meta-analysis and relative treatment effects between all regimens were obtained. Treatment-by-covariate interactions were included where possible to improve the similarity of the trials.Indacaterol 150 μg resulted in a higher change from baseline (CFB) in FEV(1) at 12 weeks compared to FOR/BUD 9/160 μg (difference in CFB 0.11 L [95% credible intervals: 0.08, 0.13]) and FOR/BUD 9/320 μg (0.09 L [0.06, 0.11]) and was comparable to SAL/FP 50/250 μg (0.02 L [-0.04, 0.08]) and SAL/FP 50/500 μg (0.03 L [0.00, 0.06]). Similar results were observed for indacaterol 300 μg at 12 weeks and indacaterol 150/300 μg at 6 months. Indacaterol 150 μg demonstrated comparable improvement in SGRQ total score at 6 months versus FOR/BUD (both doses), and SAL/FP 50/500 μg (-2.16 point improvement [-4.96, 0.95]). Indacaterol 150 and 300 μg demonstrated comparable TDI scores versus SAL/FP 50/250 μg (0.21 points (-0.57, 0.99); 0.39 [-0.39, 1.17], respectively) and SAL/FP 50/500 μg at 6 months.Indacaterol monotherapy is expected to be at least as good as FOR/BUD (9/320 and 9/160 μg) and comparable to SAL/FP (50/250 and 50/500 μg) in terms of lung function. Indacaterol is also expected to be comparable to FOR/BUD (9/320 and 9/160 μg) and SAL/FP 50/500 μg in terms of health status and to SAL/FP (50/250 and 50/500 μg) in terms of breathlessness." @default.
• W2127172644 created "2016-06-24" @default.
• W2127172644 creator A5013727360 @default.
• W2127172644 creator A5016531633 @default.
• W2127172644 creator A5045372967 @default.
• W2127172644 creator A5052012900 @default.
• W2127172644 creator A5064856948 @default.
• W2127172644 date "2011-06-01" @default.
• W2127172644 modified "2023-09-30" @default.
• W2127172644 title "Comparative efficacy of indacaterol 150 µg and 300 µg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease – a network meta-analysis" @default.
• W2127172644 cites W1517555081 @default.
• W2127172644 cites W1569625389 @default.
• W2127172644 cites W1967385770 @default.
• W2127172644 cites W2004780292 @default.
• W2127172644 cites W2006193143 @default.
• W2127172644 cites W2009498514 @default.
• W2127172644 cites W2057984874 @default.
• W2127172644 cites W2058580481 @default.
• W2127172644 cites W2084702877 @default.
• W2127172644 cites W2113144077 @default.
• W2127172644 cites W2117079401 @default.
• W2127172644 cites W2120629366 @default.
• W2127172644 cites W2123772853 @default.
• W2127172644 cites W2125779455 @default.
• W2127172644 cites W2130703359 @default.
• W2127172644 cites W2134143967 @default.
• W2127172644 cites W2139397407 @default.
• W2127172644 cites W2142724633 @default.
• W2127172644 cites W2155772830 @default.
• W2127172644 cites W2170298115 @default.
• W2127172644 doi "https://doi.org/10.2147/copd.s18759" @default.
• W2127172644 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3119108" @default.
• W2127172644 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21697997" @default.
• W2127172644 hasPublicationYear "2011" @default.
• W2127172644 type Work @default.
• W2127172644 sameAs 2127172644 @default.
• W2127172644 citedByCount "22" @default.
• W2127172644 countsByYear W21271726442012 @default.
• W2127172644 countsByYear W21271726442013 @default.
• W2127172644 countsByYear W21271726442014 @default.
• W2127172644 countsByYear W21271726442016 @default.
• W2127172644 countsByYear W21271726442017 @default.
• W2127172644 countsByYear W21271726442018 @default.
• W2127172644 countsByYear W21271726442019 @default.
• W2127172644 crossrefType "journal-article" @default.
• W2127172644 hasAuthorship W2127172644A5013727360 @default.
• W2127172644 hasAuthorship W2127172644A5016531633 @default.
• W2127172644 hasAuthorship W2127172644A5045372967 @default.
• W2127172644 hasAuthorship W2127172644A5052012900 @default.
• W2127172644 hasAuthorship W2127172644A5064856948 @default.
• W2127172644 hasBestOaLocation W21271726441 @default.
• W2127172644 hasConcept C126322002 @default.
• W2127172644 hasConcept C142724271 @default.
• W2127172644 hasConcept C204787440 @default.
• W2127172644 hasConcept C27081682 @default.
• W2127172644 hasConcept C2776042228 @default.
• W2127172644 hasConcept C2776136866 @default.
• W2127172644 hasConcept C2776719499 @default.
• W2127172644 hasConcept C2776780178 @default.
• W2127172644 hasConcept C2778884479 @default.
• W2127172644 hasConcept C2779871671 @default.
• W2127172644 hasConcept C2781018748 @default.
• W2127172644 hasConcept C2781212218 @default.
• W2127172644 hasConcept C42219234 @default.
• W2127172644 hasConcept C71924100 @default.
• W2127172644 hasConceptScore W2127172644C126322002 @default.
• W2127172644 hasConceptScore W2127172644C142724271 @default.
• W2127172644 hasConceptScore W2127172644C204787440 @default.
• W2127172644 hasConceptScore W2127172644C27081682 @default.
• W2127172644 hasConceptScore W2127172644C2776042228 @default.
• W2127172644 hasConceptScore W2127172644C2776136866 @default.
• W2127172644 hasConceptScore W2127172644C2776719499 @default.
• W2127172644 hasConceptScore W2127172644C2776780178 @default.
• W2127172644 hasConceptScore W2127172644C2778884479 @default.
• W2127172644 hasConceptScore W2127172644C2779871671 @default.
• W2127172644 hasConceptScore W2127172644C2781018748 @default.
• W2127172644 hasConceptScore W2127172644C2781212218 @default.
• W2127172644 hasConceptScore W2127172644C42219234 @default.
• W2127172644 hasConceptScore W2127172644C71924100 @default.
• W2127172644 hasLocation W21271726441 @default.
• W2127172644 hasLocation W21271726442 @default.
• W2127172644 hasLocation W21271726443 @default.
• W2127172644 hasLocation W21271726444 @default.
• W2127172644 hasOpenAccess W2127172644 @default.
• W2127172644 hasPrimaryLocation W21271726441 @default.
• W2127172644 hasRelatedWork W1603070145 @default.
• W2127172644 hasRelatedWork W1877054624 @default.
• W2127172644 hasRelatedWork W2024945270 @default.
• W2127172644 hasRelatedWork W2053463673 @default.
• W2127172644 hasRelatedWork W2075905701 @default.
• W2127172644 hasRelatedWork W2079028334 @default.
• W2127172644 hasRelatedWork W2127172644 @default.
• W2127172644 hasRelatedWork W2165363684 @default.
• W2127172644 hasRelatedWork W2326189531 @default.
• W2127172644 hasRelatedWork W3190448963 @default.
• W2127172644 isParatext "false" @default.
• W2127172644 isRetracted "false" @default.
• W2127172644 magId "2127172644" @default.

• next